BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:57 PM
 | 
Oct 17, 2012
 |  BC Extra  |  Company News

Covagen, Mitsubishi in deal for bispecific FynomAbs

Covagen AG (Zurich, Switzerland) will use its Fynomer protein engineering technology to develop bispecific proteins against two undisclosed target pairs from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508). For the first target pair,...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >